# Mira-55 Shows No THC- or Rimonabant-Linked CNS Side Effects in Preclinical Tests > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cb1-receptor-modulation-mira-55-no-cns-side-effects/ > **Published:** 2026-03-23T13:02:12-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:41:35-04:00 > **Clinical Summary:** Mira-55 demonstrates promising CB1 receptor modulation without CNS side effects, advancing cannabinoid drug development for metabolic health. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Cb1 Receptors[Drug Development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/)Metabolic HealthCns SafetyPharmaceutical Research Why This Matters MIRA-55 represents a potential breakthrough in [cannabinoid pharmacology](https://cedclinic.com/cannabinoid-drug-interactions-clinical-evidence/) by targeting CB1 receptors without the psychoactive effects of THC or the severe psychiatric risks that led to rimonabant’s withdrawal. If confirmed in human trials, this could provide therapeutic cannabinoid effects for conditions like obesity and metabolic disorders while avoiding CNS complications that have limited clinical adoption. Clinical Summary MIRA-55 is a novel cannabinoid compound that appears to modulate CB1 receptor activity without producing the central nervous system side effects associated with THC (euphoria, impairment) or rimonabant (depression, suicidality). Preclinical testing suggests selective peripheral CB1 activity or a unique receptor interaction profile. The compound aims to harness therapeutic benefits of cannabinoid system modulation while avoiding the CNS liabilities that have restricted clinical use of both CB1 agonists and antagonists. This is early-stage preclinical data requiring validation in human studies. Dr. Caplan’s Take “The holy grail in cannabinoid medicine has always been separating therapeutic effects from psychoactivity and psychiatric risks. While promising, we’ve seen many preclinical compounds fail to translate their selectivity to humans — the proof will be in Phase I safety trials.” Clinical Perspective 🧠 Clinicians should view this as interesting early research rather than imminent clinical application. The cannabinoid field has a history of promising preclinical findings that don’t translate to humans. Monitor for peer-reviewed publications and FDA trial approvals before considering clinical relevance. Current [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) remain the evidence-based standard for approved indications. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Mira-55%20Shows%20No%20THC-%20or%20Rimonabant-Linked%20CNS%20Side%20Effects%20in%20Preclinical%20Tests%20%40drcaplan&url=https%3A//www.tradingview.com/news/tradingview%3A3652d557a59f1%3A0-mira-pharmaceuticals-mira-55-shows-no-thc-or-rimonabant-linked-cns-side-effects-in-preclinical-tests/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.tradingview.com/news/tradingview%3A3652d557a59f1%3A0-mira-pharmaceuticals-mira-55-shows-no-thc-or-rimonabant-linked-cns-side-effects-in-preclinical-tests/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Mira-55%20Shows%20No%20THC-%20or%20Rimonabant-Linked%20CNS%20Side%20Effects%20in%20Preclinical%20Tests%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.tradingview.com/news/tradingview%3A3652d557a59f1%3A0-mira-pharmaceuticals-mira-55-shows-no-thc-or-rimonabant-linked-cns-side-effects-in-preclinical-tests/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.tradingview.com/news/tradingview:3652d557a59f1:0-mira-pharmaceuticals-mira-55-shows-no-thc-or-rimonabant-linked-cns-side-effects-in-preclinical-tests/](https://www.tradingview.com/news/tradingview:3652d557a59f1:0-mira-pharmaceuticals-mira-55-shows-no-thc-or-rimonabant-linked-cns-side-effects-in-preclinical-tests/) Table of Contents - [FAQ](#FAQ)[What are CB1 receptors and why are they important?](#What_are_CB1_receptors_and_why_are_they_important) - [How does CB1 receptor research relate to drug development?](#How_does_CB1_receptor_research_relate_to_drug_development) - [What is the connection between CB1 receptors and metabolic health?](#What_is_the_connection_between_CB1_receptors_and_metabolic_health) - [What are the CNS safety concerns with CB1 receptor targeting?](#What_are_the_CNS_safety_concerns_with_CB1_receptor_targeting) - [Why is this development considered clinically relevant?](#Why_is_this_development_considered_clinically_relevant) - [Related](#Related) ## FAQ #### What are CB1 receptors and why are they important? CB1 receptors are [cannabinoid receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/) found throughout the central nervous system and other tissues. They play crucial roles in regulating various physiological processes including metabolism, pain perception, and neurological function. #### How does CB1 receptor research relate to drug development? CB1 receptors are promising targets for developing new medications for conditions like obesity, diabetes, and neurological disorders. Pharmaceutical companies are actively researching compounds that can selectively interact with these receptors to create more effective treatments. #### What is the connection between CB1 receptors and metabolic health? CB1 receptors help regulate appetite, energy balance, and glucose metabolism. Targeting these receptors could lead to new treatments for metabolic disorders such as obesity and type 2 diabetes. #### What are the CNS safety concerns with CB1 receptor targeting? Since CB1 receptors are abundant in the brain, drugs targeting them can potentially cause central nervous system side effects. Researchers must carefully balance therapeutic benefits with potential neurological and psychiatric risks. #### Why is this development considered clinically relevant? This research represents emerging findings that could significantly impact patient care and treatment options. The clinical relevance rating indicates these developments are worth monitoring closely for potential therapeutic applications. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Mira-55 Shows No THC- or Rimonabant-Linked CNS Side Effects in Preclinical Tests”, “url”: “https://www.tradingview.com/news/tradingview:3652d557a59f1:0-mira-pharmaceuticals-mira-55-shows-no-thc-or-rimonabant-linked-cns-side-effects-in-preclinical-tests/”, “datePublished”: “2026-03-23T13:47:45Z”, “about”: “mira 55 shows no thc rimonabant”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS …](https://cedclinic.com/synthetic-cannabinoids-cns-side-effects-mira-55-research/) Detailed report on Mira-55’s preclinical findings confirming absence of CNS side effects linked to THC or rimonabant. [Read More](https://cedclinic.com/synthetic-cannabinoids-cns-side-effects-mira-55-research/) [New Research Shows Cannabis Compounds May Boost Liver and Heart Health](https://cedclinic.com/cardiovascular-hepatic-safety-cannabis-research/) Explore emerging research on [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) improving metabolic and cardiovascular health outcomes. [Explore Research](https://cedclinic.com/cardiovascular-hepatic-safety-cannabis-research/) [FDA-Approved CBD Drug Shows Early Promise in Anorexia Patients](https://cedclinic.com/fda-approved-cbd-drug-anorexia-promise/) Insights into cannabinoid-based therapies demonstrating clinical potential beyond psychoactive effects. [Learn More](https://cedclinic.com/fda-approved-cbd-drug-anorexia-promise/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).